EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

CAR T‐cell therapy in large B cell lymphoma

Alexander P Boardman, Gilles Salles

Hematological Oncology · 2023-06 · 41 (S1) · 112-118

DOI: 10.1002/hon.3153 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematological Oncology, online erschienen am 09.06.2023. Verfasst von Alexander P Boardman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, New York, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD19‐targeted chimeric antigen receptor (CAR) T‐cells have revolutionized the treatment of lymphoid malignancies, including large B cell lymphoma (LBCL). Following seminal early phase multicenter clinical trials published between 2017 and 2020, three CD19‐CAR T‐cell products received FDA and EMA approval designations in lymphoma in the third‐line setting, paving the way for follow‐up studies in the second‐line. Meanwhile, investigations into the applications of CAR T‐cell therapy have further broadened to treating high‐risk patients even prior to completion of first‐line conventional chemo‐immunotherapy. Furthermore, as early trials excluded patients with central nervous system involvement with lymphoma, several studies have recently shown promising efficacy of CD19‐CAR T‐cells in primary and secondary CNS lymphoma. Here we provide a detailed overview on clinical data supporting the use of CAR T‐cells in patients with LBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseCentral Nervous System NeoplasmsHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellT-LymphocytesAntigens, CD19Multicenter Studies as Topic

Stichwörter der Autor:innen

B-cell lymphomaCD19autologous stem cell transplantation (ASCT)chimeric antigen receptor (CAR) T celldiffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)primary CNS lymphoma (PCNSL)secondary CNS lymphoma (SCNSL)

Substanzen

Receptors, Antigen, T-CellAntigens, CD19

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, New York, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Boardman, A. P., & Salles, G. (2023). CAR T‐cell therapy in large B cell lymphoma. Hematological Oncology, 41(S1), 112-118. https://doi.org/10.1002/hon.3153

Vancouver

Boardman AP, Salles G. CAR T‐cell therapy in large B cell lymphoma. Hematological Oncology. 2023;41(S1):112-118. doi:10.1002/hon.3153

BibTeX
@article{Boardman2023,
  author = {Boardman, Alexander P and Salles, Gilles},
  title = {CAR T‐cell therapy in large B cell lymphoma},
  journal = {Hematological Oncology},
  year = {2023},
  volume = {41},
  number = {S1},
  pages = {112--118},
  doi = {10.1002/hon.3153}
}
Kostenlos starten →